FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Reviva Pharmaceuticals Holdings, Inc. Stock AnalysisComprehensive stock analysis for Reviva Pharmaceuticals Holdings, Inc. (RVPHW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRVPHW
RVPHW
Reviva Pharmaceuticals Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RVPHW
Home🔹Stocks🔹Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc.

RVPHW•NASDAQ

Reviva Pharmaceuticals Holdings, Inc.

RVPHW•NASDAQ
Market cap
$343.91K
Sentiment

Your view on RVPHW

Mkt Cap
$343.91K
Sentiment
Your view
RVPHW
Reviva Pharmaceuticals Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RVPHW
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Reviva Pharmaceuticals Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Laxminarayan Bhat
Headquarters
19925 Stevens Creek Boulevard, Cupertino, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Laxminarayan Bhat
Headquarters
19925 Stevens Creek Boulevard, Cupertino, CA, US
Description

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for diseases with substantial unmet medical needs. Their pipeline targets disorders within the central nervous system, respiratory, cardiovascular, metabolic, and inflammatory disease categories. The company's leading drug candidate, brilaroxazine (RP5063), is currently in Phase III clinical trials for the treatment of schizophrenia. This compound has also completed Phase I trials for a diverse set of conditions, including bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, the behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. Furthermore, Reviva is advancing RP1208, which is in pre-clinical development for depression and obesity. Founded in 2018, the company is headquartered in Cupertino, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

FRC's fair value estimate for Reviva Pharmaceuticals Holdings, Inc., and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Reviva Pharmaceuticals Holdings, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Reviva Pharmaceuticals Holdings, Inc.. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Reviva Pharmaceuticals Holdings, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Reviva Pharmaceuticals Holdings, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Reviva Pharmaceuticals Holdings, Inc. valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Which institutions hold Reviva Pharmaceuticals Holdings, Inc., and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

Buying and selling by Reviva Pharmaceuticals Holdings, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Reviva Pharmaceuticals Holdings, Inc.. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Reviva Pharmaceuticals Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Reviva Pharmaceuticals Holdings, Inc.. Press releases and market coverage, newest first.

News

Latest Market News